title: Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052).
abstract: The HIV Prevention Trials Network 052 study enrolled serodiscordant couples. Index participants infected with human immunodeficiency virus reported no prior antiretroviral (ARV) treatment at enrollment. ARV drug testing was performed retrospectively using enrollment samples from a subset of index participants. ARV drugs were detected in 45 of 96 participants (46.9%) with an undetectable viral load, 2 of 48 (4.2%) with a low viral load, and 1 of 65 (1.5%) with a high viral load (P < .0001); they were also detected in follow-up samples from participants who were not receiving study-administered treatment. ARV drug testing may be useful in addition to self-report of ARV drug use in some clinical trial settings.
authors.affiliation: Department of Pathology.
authors.forename: Jessica M
authors.initials: JM
authors.lastname: Fogel
authors.forename: Lei
authors.initials: L
authors.lastname: Wang
authors.forename: Teresa L
authors.initials: TL
authors.lastname: Parsons
authors.forename: San-San
authors.initials: SS
authors.lastname: Ou
authors.forename: Estelle
authors.initials: E
authors.lastname: Piwowar-Manning
authors.forename: Ying
authors.initials: Y
authors.lastname: Chen
authors.forename: Victor O
authors.initials: VO
authors.lastname: Mudhune
authors.forename: Mina C
authors.initials: MC
authors.lastname: Hosseinipour
authors.forename: Johnstone
authors.initials: J
authors.lastname: Kumwenda
authors.forename: James G
authors.initials: JG
authors.lastname: Hakim
authors.forename: Suwat
authors.initials: S
authors.lastname: Chariyalertsak
authors.forename: Ravindre
authors.initials: R
authors.lastname: Panchia
authors.forename: Ian
authors.initials: I
authors.lastname: Sanne
authors.forename: Nagalingeswaran
authors.initials: N
authors.lastname: Kumarasamy
authors.forename: Beatriz
authors.initials: B
authors.lastname: Grinsztejn
authors.forename: Joseph
authors.initials: J
authors.lastname: Makhema
authors.forename: Jose
authors.initials: J
authors.lastname: Pilotto
authors.forename: Breno R
authors.initials: BR
authors.lastname: Santos
authors.forename: Kenneth H
authors.initials: KH
authors.lastname: Mayer
authors.forename: Marybeth
authors.initials: M
authors.lastname: McCauley
authors.forename: Theresa
authors.initials: T
authors.lastname: Gamble
authors.forename: Namandjé N
authors.initials: NN
authors.lastname: Bumpus
authors.forename: Craig W
authors.initials: CW
authors.lastname: Hendrix
authors.forename: Myron S
authors.initials: MS
authors.lastname: Cohen
authors.forename: Susan H
authors.initials: SH
authors.lastname: Eshleman
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008297:Male; D012307:Risk Factors; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents
keywords: Africa; HIV; HPTN 052; antiretroviral drug; clinical trial; self-report
references.citation: N Engl J Med. 2012 Aug 2;367(5):423-34
references.pmid: 22784038
references.citation: N Engl J Med. 2010 Dec 30;363(27):2587-99
references.pmid: 21091279
references.citation: Pain Med. 2007 Mar;8(2):171-83
references.pmid: 17305688
references.citation: N Engl J Med. 2011 Aug 11;365(6):493-505
references.pmid: 21767103
references.citation: N Engl J Med. 2012 Aug 2;367(5):399-410
references.pmid: 22784037
references.citation: J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):334-8
references.pmid: 23187947
references.citation: Lancet Infect Dis. 2013 Jan;13(1):10-2
references.pmid: 23257221
references.citation: N Engl J Med. 2010 Feb 4;362(5):427-39
references.pmid: 20089951